Hemostemix Contracts Empire Market Ventures to Increase Market Awareness

Company Overview - Hemostemix is an autologous stem cell therapy platform company founded in 2003, recognized as a World Economic Forum Technology Pioneer [2] - The company has developed and patented VesCell™ (ACP-01), a blood-based stem cell therapy, and is scaling its production and sales [2] - Hemostemix has completed seven clinical studies involving 318 subjects, with results published in 11 peer-reviewed publications [2] Clinical Achievements - ACP-01 has shown safety and clinical relevance as a treatment for various conditions, including peripheral arterial disease and chronic limb threatening ischemia [2] - The Phase II clinical trial for chronic limb threatening ischemia reported a 0% mortality rate and 83% wound healing in patients followed for up to 4.5 years, compared to a 50% mortality rate in the general patient population [2] Recent Developments - Hemostemix has contracted Empire Market Ventures to enhance market awareness and investor engagement [1] - Empire Market Ventures specializes in strategic communications and market intelligence, providing tailored solutions for emerging companies [1] - The partnership aims to position Hemostemix for long-term success in capital markets [1]